Disease · MONDO_0001134
Comparisons in its trials29
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 29
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Valsartan/Amlodipine 160/5 mg vs Amlodipine 10 mg: serious adverse events | 11 of 592 | 8 of 591 | 1,183 | NCT00437645 | Trial comparisons |
| Azilsartan Medoxomil and Chlorthalidone vs Olmesartan Medoxomil and Hydrochlorothiazide: serious adverse events | 24 of 418 | 26 of 419 | 837 | NCT00996281 | Trial comparisons |
| Losartan 50 mg/HCTZ 12.5 mg vs Valsartan 80 mg/HCTZ 12.5 mg: serious adverse events | 11 of 425 | 5 of 383 | 808 | NCT00546754 | Trial comparisons |
| T80/A5 vs T80/A10: serious adverse events | 1 of 501 | 1 of 232 | 733 | NCT01134393 | Trial comparisons |
| Azilsartan vs Amlodipine: serious adverse events | 0 of 359 | 5 of 359 | 718 | NCT01762501 | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | 30 of 362 | 22 of 307 | 669 | NCT00695955 | Trial comparisons |
| Eprosartan vs Eprosartan Mesylate: serious adverse events | 3 of 332 | 7 of 332 | 664 | NCT01631227 | Trial comparisons |
| Valsartan/Amlodipine 160/5 mg vs Valsartan 160 mg: serious adverse events | 0 of 329 | 1 of 325 | 654 | NCT01001572 | Trial comparisons |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD vs Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD: serious adverse events | 6 of 302 | 5 of 303 | 605 | NCT00818883 | Trial comparisons |
| Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination vs Amlodipine 5 mg Monotherapy: serious adverse events | 1 of 269 | 2 of 262 | 531 | NCT00558064 | Trial comparisons |
| Control: Losartan vs Test: Fimasartan: serious adverse events | 5 of 250 | 3 of 255 | 505 | NCT00922480 | Trial comparisons |
| LCZ696 200 mg vs Olmesartan 20 mg: Number of Patients Achieving Successful Mean Sitting Diastolic Blood Pressure (msDBP) Control | 133 of 188 | 112 of 187 | 375 | NCT01876368 | Trial comparisons |
| LCZ696 200 mg vs Olmesartan 20 mg: Number of Patients Achieving Successful Mean Sitting Diastolic Blood Pressure (msDBP) Response | 137 of 188 | 115 of 187 | 375 | NCT01876368 | Trial comparisons |
| LCZ696 200 mg vs Olmesartan 20 mg: Number of Patients Achieving Successful Mean Sitting Systolic Blood Pressure (msSBP) Control | 84 of 188 | 58 of 187 | 375 | NCT01876368 | Trial comparisons |
| LCZ696 200 mg vs Olmesartan 20 mg: Number of Patients Achieving Successful Mean Sitting Systolic Blood Pressure (msSBP) Response | 90 of 188 | 65 of 187 | 375 | NCT01876368 | Trial comparisons |
| LCZ696 200 mg vs Olmesartan 20 mg: Number of Patients Achieving Successful Overall Blood Pressure Control | 76 of 188 | 52 of 187 | 375 | NCT01876368 | Trial comparisons |
| LCZ696 200 mg vs Olmesartan 20 mg: serious adverse events | 0 of 188 | 2 of 187 | 375 | NCT01876368 | Trial comparisons |
| LCZ696 Monotherapy vs LCZ696 Combination Therapy: Number of Participants With Blood Pressure Control Rate of <140/90 mmHg (Analysis by Mono or Combination Therapy) | 176 of 228 | 80 of 112 | 340 | NCT01256411 | Trial comparisons |
| MK-0954A vs Losartan: serious adverse events | 0 of 166 | 0 of 170 | 336 | NCT01307046 | Trial comparisons |
| L50/H12.5/A5 vs L50 + A5: serious adverse events | 1 of 164 | 1 of 163 | 327 | NCT01302691 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001134/comparisons